Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline

达拉图穆马 医学 指南 多发性骨髓瘤 重症监护医学 医疗保健 梅德林 来那度胺 家庭医学 介绍 耐火材料(行星科学) 疾病 肿瘤科
作者
Lisa K. Hicks,Hans J. Messersmith,Samer S.A. Al Hadidi,Rahul Kumar Banerjee,Benjamin Avi Derman,Shaji Kunnathu Kumar,Tanya Marya Wildes,Susan Bal,Sita Bhella,Cynthia Chmielewski,Caitlin L. Costello,Raetasha Sheavette Dabney,Monique A. Hartley-Brown,Alan D. Langerak,Brea C. Lipe,Thomas Martin,Arleigh B. Robertson McCurdy,Hira S. Mian,Eloísa Riva,Rahul Seth
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (10): 914-941 被引量:16
标识
DOI:10.1200/jco-25-02587
摘要

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE To provide updated guidance regarding the therapy for multiple myeloma. METHODS ASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature. RESULTS The updated review identified a total of 161 relevant randomized trials. UPDATED RECOMMENDATIONS Daratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles. Additional information is available at www.asco.org/hematologic-malignancies-guidelines .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刘奇发布了新的文献求助10
刚刚
王智发布了新的文献求助10
刚刚
经竺的应助被cola采纳,获得10
刚刚
slk发布了新的文献求助10
刚刚
在水一方的应助被tianzhen采纳,获得10
刚刚
Azure完成签到 ,获得积分10
1秒前
shuo关注了科研通微信公众号
1秒前
王多余完成签到,获得积分10
1秒前
1秒前
1233完成签到,获得积分20
2秒前
叶子发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
muyu完成签到,获得积分10
3秒前
学学球完成签到,获得积分10
4秒前
Christoph_Lee发布了新的文献求助10
4秒前
荼蘼发布了新的文献求助10
4秒前
5秒前
我是老大的应助被Wang采纳,获得10
5秒前
鹤轸完成签到 ,获得积分10
5秒前
5秒前
风中远山完成签到,获得积分10
6秒前
Health完成签到 ,获得积分10
6秒前
wanci的应助被霁月采纳,获得10
6秒前
mes发布了新的文献求助10
6秒前
wanci的应助被竹叶听清采纳,获得10
6秒前
6秒前
英姑的应助被zs采纳,获得10
6秒前
星辰大海的应助被上官小怡采纳,获得10
7秒前
酷波er的应助被朴素毛豆采纳,获得10
7秒前
7秒前
ZM关闭了ZM的文献求助
7秒前
元吉的应助被迪迪张采纳,获得10
7秒前
Orange的应助被包子采纳,获得10
7秒前
秋风的应助被shufei采纳,获得10
8秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180807
求助须知:如何正确求助?哪些是违规求助? 9570895
关于积分的说明 21815089
捐赠科研通 7777155
什么是DOI,文献DOI怎么找? 3433347
关于科研通互助平台的介绍 2557613
邀请新用户注册赠送积分活动 2479317